329 related articles for article (PubMed ID: 35977284)
1. Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic.
Tilhou AS; Dague L; Saloner B; Beemon D; Burns M
JAMA Health Forum; 2022 Mar; 3(3):e220093. PubMed ID: 35977284
[TBL] [Abstract][Full Text] [Related]
2. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
3. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
4. Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic.
Nguyen T; Ziedan E; Simon K; Miles J; Crystal S; Samples H; Gupta S
JAMA Netw Open; 2022 Jun; 5(6):e2214765. PubMed ID: 35648400
[TBL] [Abstract][Full Text] [Related]
5. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
[TBL] [Abstract][Full Text] [Related]
6. Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge.
Solomon KT; O'Connor J; Gibbons JB; Kilaru AS; Feder KA; Xue L; Saloner B; Stuart EA; Cole ES; Hulsey E; Meisel Z; Patel E; Donohue JM
JAMA Health Forum; 2023 Mar; 4(3):e230245. PubMed ID: 36961457
[TBL] [Abstract][Full Text] [Related]
7. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
Grove LR; Rao N; Domino ME
Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
[TBL] [Abstract][Full Text] [Related]
8. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
[TBL] [Abstract][Full Text] [Related]
9. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine Utilization and Prescribing Among New Jersey Medicaid Beneficiaries After Adoption of Initiatives Designed to Improve Treatment Access.
Treitler P; Nowels M; Samples H; Crystal S
JAMA Netw Open; 2023 May; 6(5):e2312030. PubMed ID: 37145594
[TBL] [Abstract][Full Text] [Related]
11. Trends in Use of Medication to Treat Opioid Use Disorder During the COVID-19 Pandemic in 10 State Medicaid Programs.
Austin AE; Tang L; Kim JY; Allen L; Barnes AJ; Chang CH; Clark S; Cole ES; Durrance CP; Donohue JM; Gordon AJ; Huskamp HA; McDuffie MJ; Mehrotra A; Mohamoud S; Talbert J; Ahrens KA; Applegate M; Hammerslag LR; Lanier P; Tossone K; Zivin K; Burns ME
JAMA Health Forum; 2023 Jun; 4(6):e231422. PubMed ID: 37327009
[TBL] [Abstract][Full Text] [Related]
12. Racial‒Ethnic Disparities of Buprenorphine and Vivitrol Receipt in Medicaid.
Dunphy CC; Zhang K; Xu L; Guy GP
Am J Prev Med; 2022 Nov; 63(5):717-725. PubMed ID: 35803789
[TBL] [Abstract][Full Text] [Related]
13. Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic.
Tanz LJ; Jones CM; Davis NL; Compton WM; Baldwin GT; Han B; Volkow ND
JAMA Netw Open; 2023 Jan; 6(1):e2251856. PubMed ID: 36662523
[TBL] [Abstract][Full Text] [Related]
14. Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.
Miles J; Treitler P; Hermida R; Nyaku AN; Simon K; Gupta S; Crystal S; Samples H
Drug Alcohol Depend; 2023 Nov; 252():110963. PubMed ID: 37748421
[TBL] [Abstract][Full Text] [Related]
15. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
Currie JM; Schnell MK; Schwandt H; Zhang J
JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
[TBL] [Abstract][Full Text] [Related]
16. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.
Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC
J Subst Use Addict Treat; 2024 Feb; 157():209271. PubMed ID: 38135120
[TBL] [Abstract][Full Text] [Related]
17. Utilization and disparities in medication treatment for opioid use disorder among patients with comorbid opioid use disorder and chronic pain during the COVID-19 pandemic.
Perry A; Wheeler-Martin K; Hasin DS; Terlizzi K; Mannes ZL; Jent V; Townsend TN; Pamplin JR; Crystal S; Martins SS; Cerdá M; Krawczyk N
Drug Alcohol Depend; 2023 Dec; 253():111023. PubMed ID: 37984034
[TBL] [Abstract][Full Text] [Related]
18. Association Between Buprenorphine Treatment Gaps, Opioid Overdose, and Health Care Spending in US Medicare Beneficiaries With Opioid Use Disorder.
Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC
JAMA Psychiatry; 2022 Dec; 79(12):1173-1179. PubMed ID: 36197659
[TBL] [Abstract][Full Text] [Related]
19. Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020.
Cremer LJ; Board A; Guy GP; Schieber L; Asher A; Parker EM
Drug Alcohol Depend; 2022 Mar; 232():109192. PubMed ID: 35065513
[TBL] [Abstract][Full Text] [Related]
20. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
